828 results on '"Serody, Jonathan S."'
Search Results
102. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new
103. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
104. Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia
105. The Role of Lactoferrin as an Anti-Inflammatory Molecule
106. CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease
107. The Control of Cytomegalovirus Infection: Chemotherapy
108. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1–dependent mechanism that is up-regulated by interleukin-13
109. Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells
110. Anti–PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells
111. CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients
112. CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma
113. Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
114. In vitro–differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations
115. Blastomycosis in Transplant Recipients: Report of a Case and Review
116. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection
117. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)
118. Infusion of CD30 CAR T Cells Is Safe and Effective As Consolidation Following Autologous Hematopoietic Stem Cell Transplant
119. CD200 is induced by ERK and is a potential therapeutic target in melanoma
120. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients
121. Chemokines and graft-versus-host disease
122. Contributors
123. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice
124. Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
125. STING agonist promotes CAR T cell trafficking and persistence in breast cancer
126. Infections fongiques
127. Contributeurs
128. Contributors
129. Fungal Infections
130. Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease
131. Chapter 18 - Chemokines and Graft-Versus-Host Disease
132. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
133. Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia
134. Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)
135. Abstract 2866: Neoantigen nanovaccine improves personalized cancer immunotherapy
136. Inhibiting fatty acid synthesis (FAS) can prevent and treat chronic graft versus host disease (cGVHD)
137. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients
138. Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease
139. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease
140. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM)
141. Cytoprotection by Amifostine during Autologous Stem Cell Transplantation for Advanced Refractory Hematologic Malignancies
142. L-Selectinhi but not the L-selectinlo CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection
143. In vivo imaging of graft-versus-host-disease in mice
144. BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes
145. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1α (CCL3) after allogeneic BMT in mice
146. 64 - CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/ Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma
147. An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies
148. The effect of oral mucositis on morbidity and mortality in bone marrow transplant
149. Fever in Immunocompromised Patients
150. The Immune Landscape of Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.